mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors
Conclusions:
mTOR-inhibitor treatment with sirolimus for ≥3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients.
Clinical Trial Registration:
EudraCT: 2005-005362-36
Clinicaltrials.gov:
NCT00355862.
Source: Annals of Surgery - Category: Surgery Tags: PAPERS CHOSEN FOR PRESENTATION AT THE 2020 ANNUAL MEETING OF THE EUROPEAN SURGICAL ASSOCIATION Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hepatocellular Carcinoma | Learning | Liver | Liver Cancer | Liver Transplant | Study | Surgery | Transplants | Universities & Medical Training | Urology & Nephrology